Precipio Inc. (NASDAQ: PRPO) stock gained by 22.49% in the current market trading. Precipio has created a program that aims to eliminate misdiagnosis by using the intellect, experience, and technologies gained within academic institutions by providing high-quality diagnostic information to physicians and their patients around the world, as well as proprietary goods that service laboratories around the world.
What is coming ahead?
On Thursday, May 20th, Precipio will hold its Q1-2021 corporate update call. All of PRPO’s new core businesses will be discussed during the call.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Recent Past Development
PRPO revealed on May 10, 2021, the introduction of a new four-hour Acute Myeloid Leukemia (AML) HemeScreen panel to assess the genetics of this aggressive, acute type of leukemia. Physicians can quickly and accurately choose the most appropriate targeted therapeutic because they know the genetic character of the condition.
Apart from the great clinical utility and significant effect on patient care mentioned below, this platform is expected to rise revenues to Oncology Physician Office Laboratories by nearly 10% (depending on patient volume), and Precipio’s revenues from current and future Oncology POL and other laboratory customers that integrate this panel into the system are projected to increase likewise.
The inclusion of this panel further highlights HemeScreen’s capacity and the POL model, in which an established deployed customer base, as well as Precipio, gain from Precipio’s R&D team’s ongoing growth and launch of new panels.
Ilan Danieli, Precipio’s Chief Executive Officer commented:
PRPO’s R&D team’s ability to both recognize clinically relevant testing needs and develop products that meet these needs, with patient safety at the forefront of their vision, is the bedrock of HemeScreen’s clinical and commercial success. This panels would allow POLs to quickly diagnose patient illness and deliver immediate and therefore improved, treatment to their patients, while also benefiting PRPO financially and operationally. PRPO is looking forward to the release of the AML and other upcoming committees.
